The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review.

Abstract:

:The issue of antipsychotic treatment during pregnancy is subject to substantial uncertainty and some controversy among healthcare providers, specifically pertaining to second-generation antipsychotics (SGAs) that are subject to a large gap in safety data during pregnancy compared with antidepressants. The amount of safety data for the use of SGAs during pregnancy is rapidly increasing, thus constantly changing the level of evidence. We performed a clinically focused review on the safety of SGA during pregnancy. Twenty-three studies provided various pregnancy outcomes for 14,382 pregnant women exposed to an SGA during pregnancy. In utero exposure to aripiprazole, olanzapine, and quetiapine is not associated with increased risks of major congenital malformations, whereas risperidone and paliperidone may be associated with a very minor increased risk of congenital malformations. Safety data on ziprasidone and clozapine remain scarce and insufficient for a quantitative safety evaluation. No or minimal safety data are available for amisulpride, asenapine, lurasidone, and sertindole. For other pregnancy outcomes of interest, e.g. miscarriage, stillbirth, and small for gestational age, the available data overall do not suggest a clinically important increased risk, and do not allow for a meaningful stratification on individual drug level. Furthermore, for neonatal adaption and childhood neurodevelopment, the data do not allow for a meaningful risk assessment. It is imperative that factors in addition to safety data, e.g. individual disease history, characteristics and treatment response, adverse reaction profile, and patient preferences, be considered for the individual patient when choosing specific SGA treatment during pregnancy.

journal_name

CNS Drugs

journal_title

CNS drugs

authors

Damkier P,Videbech P

doi

10.1007/s40263-018-0517-5

subject

Has Abstract

pub_date

2018-04-01 00:00:00

pages

351-366

issue

4

eissn

1172-7047

issn

1179-1934

pii

10.1007/s40263-018-0517-5

journal_volume

32

pub_type

杂志文章,评审
  • Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.

    abstract::Oral fingolimod (Gilenya™), a sphingosine 1-phosphate (S1P) receptor agonist, is the first oral agent and the first in a novel class of disease-modifying therapies (DMTs) to be approved for use in the US for the treatment of relapsing forms of multiple sclerosis (MS). In the EU, fingolimod is approved for use as a sin...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11207350-000000000-00000

    authors: Scott LJ

    更新日期:2011-08-01 00:00:00

  • Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.

    abstract:BACKGROUND:Several small studies have shown beneficial effects of ondansetron, a serotonin 5-HT(3) receptor antagonist, in the treatment of obsessive-compulsive disorder (OCD). The efficacy of other 5-HT(3) receptor antagonists in patients with OCD is still unclear. Granisetron does not alter cytochrome P450 activity a...

    journal_title:CNS drugs

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.2165/11635850-000000000-00000

    authors: Askari N,Moin M,Sanati M,Tajdini M,Hosseini SM,Modabbernia A,Najand B,Salimi S,Tabrizi M,Ashrafi M,Hajiaghaee R,Akhondzadeh S

    更新日期:2012-10-01 00:00:00

  • Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations.

    abstract::Premature mortality due to cardiovascular disease in those with schizophrenia is the largest lifespan disparity in the US and is growing; adults in the US with schizophrenia die, on average, 28 years earlier than those in the general population. The rate of smoking prevalence among individuals with schizophrenia is es...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-017-0438-8

    authors: Cather C,Pachas GN,Cieslak KM,Evins AE

    更新日期:2017-06-01 00:00:00

  • Weight regain after discontinuation of topiramate treatment in patients with migraine: a prospective observational study.

    abstract:PURPOSE:To monitor weight regain after therapy discontinuation in patients with migraine experiencing weight loss during topiramate (TPM) treatment. METHODS:Patients with migraine without aura were enrolled in this observational prospective study. Weight, body mass index (BMI), waist circumference, systolic and diasto...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-015-0229-z

    authors: Verrotti A,Parisi P,Agostinelli S,Loiacono G,Marra F,Coppola G,Pisani LR,Gorgone G,Striano P,Pisani F,Belcastro V

    更新日期:2015-02-01 00:00:00

  • Attention-deficit/hyperactivity disorder with inadequate response to stimulants: approaches to management.

    abstract::Attention-deficit/hyperactivity disorder, or ADHD, is the most frequently occurring neurobiological disorder in childhood and is defined by symptoms of inattention and/or hyperactivity and impulsivity that are excessive when compared with other individuals at the same developmental level. ADHD can be successfully trea...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0130-6

    authors: Childress AC,Sallee FR

    更新日期:2014-02-01 00:00:00

  • Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.

    abstract::Satisfactory management of Parkinson's disease is a challenge that requires a tailored approach for each individual. In the advanced phase of the disease, patients may experience motor complications despite optimized pharmacological therapy. Apomorphine, a short-acting D1- and D2-like receptor agonist, is the only dru...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-019-00661-z

    authors: Carbone F,Djamshidian A,Seppi K,Poewe W

    更新日期:2019-09-01 00:00:00

  • Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.

    abstract:SYNOPSIS:Mirtazapine is a tetracyclic antidepressant with a novel mechanism of action; it increases noradrenergic and serotonergic neurotransmission via blockade of central α2-adrenergic auto- and heteroreceptors. The increased release of serotonin (5-hydroxytryptamine; 5-HT) stimulates serotonin 5-HT1 receptors becaus...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-199605050-00007

    authors: Davis R,Wilde MI

    更新日期:1996-05-01 00:00:00

  • Spotlight on risperidone in irritability associated with autistic disorder in children and adolescents.

    abstract::Risperidone (Risperdal), a psychotropic atypical antipsychotic agent, is thought to act via dopamine D(2) and serotonin 5-HT(2A) receptor antagonism. The clinical efficacy of oral risperidone in the treatment of bipolar mania and schizophrenia in adult patients is well established. In the US, risperidone is also appro...

    journal_title:CNS drugs

    pub_type: 评论,杂志文章

    doi:10.2165/00023210-200822030-00006

    authors: Scott LJ,Dhillon S

    更新日期:2008-01-01 00:00:00

  • VMAT2 Inhibitors in Neuropsychiatric Disorders.

    abstract::The basal ganglia and dopaminergic pathways play a central role in hyperkinetic movement disorders. Vesicular monoamine transporter 2 (VMAT2) inhibitors, which deplete dopamine at presynaptic striatal nerve terminals, are a class of drugs that have long been used to treat hyperkinetic movement disorders, but have rece...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0580-y

    authors: Tarakad A,Jimenez-Shahed J

    更新日期:2018-12-01 00:00:00

  • Therapeutic Potential of Ursolic Acid to Manage Neurodegenerative and Psychiatric Diseases.

    abstract::Ursolic acid is a pentacyclic triterpenoid found in several plants. Despite its initial use as a pharmacologically inactive emulsifier in pharmaceutical, cosmetic and food industries, several biological activities have been reported for this compound so far, including anti-tumoural, anti-diabetic, cardioprotective and...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-017-0474-4

    authors: Ramos-Hryb AB,Pazini FL,Kaster MP,Rodrigues ALS

    更新日期:2017-12-01 00:00:00

  • Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy.

    abstract::Nucleoside analogue reverse transcriptase inhibitors (NRTIs), used as part of highly active antiretroviral therapy for the treatment of HIV and AIDS, disrupt neuronal mitochondrial DNA synthesis, resulting in antiretroviral toxic neuropathy (ATN). Acetyl-L-carnitine (ALC) enhances neurotrophic support of sensory neuro...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200721001-00004

    authors: Youle M

    更新日期:2007-01-01 00:00:00

  • Does pharmacological treatment of ADHD in adults enhance parenting performance? Results of a double-blind randomized trial.

    abstract:OBJECTIVE:This study examines the effects of parental lisdexamfetamine (LDX) treatment on parent-child interactions. METHODS:Participants were 30 parents (27% were male) and their children aged 5-12 years, both diagnosed with DSM-IV attention-deficit/hyperactivity disorder (ADHD). Optimal LDX dose (30, 50, or 70 mg/da...

    journal_title:CNS drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40263-014-0165-3

    authors: Waxmonsky JG,Waschbusch DA,Babinski DE,Humphrey HH,Alfonso A,Crum KI,Bernstein M,Slavec J,Augustus JN,Pelham WE

    更新日期:2014-07-01 00:00:00

  • Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinson's Disease.

    abstract::There is escalating interest in cell-based therapies to restore lost dopamine inputs in Parkinson's disease. This is based upon the rationale that implanting dopamine progenitors into the striatum can potentially improve dopamine-responsive motor symptoms. A rich body of data describing clinical trials of previous cel...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-020-00727-3

    authors: Henchcliffe C,Sarva H

    更新日期:2020-06-01 00:00:00

  • Treatment of epileptic encephalopathies.

    abstract::Epileptic encephalopathy is defined as a condition where the epileptic activity itself may contribute to the severe neurological and cognitive impairment seen, over and above that which would be expected from the underlying pathology alone. The epilepsy syndromes at high risk of this are a disparate group of condition...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0041-6

    authors: McTague A,Cross JH

    更新日期:2013-03-01 00:00:00

  • A naturalistic study of galantamine for Alzheimer's disease.

    abstract:OBJECTIVE:To collect descriptive data on the treatment of Alzheimer's disease with galantamine under naturalistic conditions. STUDY DESIGN:This was a prospective, open-label, observational study. PATIENTS:Subjects (n = 345) with mild to moderately severe dementia of the Alzheimer's type were recruited from 48 hospita...

    journal_title:CNS drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00023210-200620110-00006

    authors: Brodaty H,Woodward M,Boundy K,Barnes N,Allen G,NATURE Investigators.

    更新日期:2006-01-01 00:00:00

  • Association Between Statin Use and Depressive Symptoms in a Large Community-Dwelling Older Population Living in Australia and the USA: A Cross-Sectional Study.

    abstract:BACKGROUND:Statin use has been frequently associated with depressive symptoms in an older population. However, the nature of this association is uncertain in the literature. In this study, we aimed to investigate the association of statin intake and the prevalence of depressive symptoms in healthy community-dwelling ol...

    journal_title:CNS drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40263-019-00633-3

    authors: Agustini B,Mohebbi M,Woods RL,McNeil JJ,Nelson MR,Shah RC,Murray AM,Ernst ME,Reid CM,Tonkin A,Lockery JE,Berk M,ASPREE Investigator Group.

    更新日期:2019-07-01 00:00:00

  • Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study.

    abstract:BACKGROUND:Earlier commencement of clozapine has been related to a better response in treatment-resistant schizophrenia. OBJECTIVES:To identify variables that predict clozapine use after a first episode of schizophrenia (FES). METHODS:Patients with FES and ≤15 days of lifetime antipsychotic treatment were followed up...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-016-0358-z

    authors: Üçok A,Çıkrıkçılı U,Ergül C,Tabak Ö,Salaj A,Karabulut S,Correll CU

    更新日期:2016-10-01 00:00:00

  • Overview of Current Drug Delivery Methods Across the Blood-Brain Barrier for the Treatment of Primary Brain Tumors.

    abstract::Existing drug delivery methods have not led to a significant increase in survival for patients with malignant primary brain tumors. While the combination of conventional therapies consisting of surgery, radiotherapy, and chemotherapy has improved survival for some types of brain tumors (e.g., WNT medulloblastoma), oth...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00766-w

    authors: Haumann R,Videira JC,Kaspers GJL,van Vuurden DG,Hulleman E

    更新日期:2020-11-01 00:00:00

  • The star systems: overview and use in determining antiepileptic drug choice.

    abstract::An explosion in antiepileptic drug (AED) therapy began in the 1990s with the licensing of 9 new chemical entities and more to come. Important differences between AEDs may not be detected by regulatory trials, which are designed to satisfy licensing requirements and often diverge considerably from everyday clinical pra...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115010-00001

    authors: Brodie MJ,Kwan P

    更新日期:2001-01-01 00:00:00

  • Blonanserin: a review of its use in the management of schizophrenia.

    abstract::Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomiz...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11202620-000000000-00000

    authors: Deeks ED,Keating GM

    更新日期:2010-01-01 00:00:00

  • Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia.

    abstract:INTRODUCTION AND OBJECTIVE:Haemorrheological parameters and endothelial function are known to be altered in vascular diseases, including stroke. Treatment with HMG-CoA reductase inhibitors ('statins') improves cerebrovascular (and cardiovascular) morbidity and mortality in patients with atherosclerosis; the beneficial ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-200418030-00003

    authors: Szapary L,Horvath B,Marton Z,Alexy T,Kesmarky G,Habon T,Szots M,Koltai K,Juricskay I,Czopf J,Toth K

    更新日期:2004-01-01 00:00:00

  • Tianeptine: a review of its use in depressive disorders.

    abstract:UNLABELLED:Tianeptine is an antidepressant agent with a novel neurochemical profile. It increases serotonin (5-hydroxytryptamine; 5-HT) uptake in the brain (in contrast with most antidepressant agents) and reduces stress-induced atrophy of neuronal dendrites. Like the selective serotonin reuptake inhibitors (SSRIs) and...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115030-00006

    authors: Wagstaff AJ,Ormrod D,Spencer CM

    更新日期:2001-01-01 00:00:00

  • Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.

    abstract::Progress in finding a better alternative to alteplase has been slow. Tenecteplase and desmoteplase have better pharmacological profiles compared with alteplase, but definite clinical evidence of their superiority is lacking. The two major phase III studies that have tested the efficacy and safety of desmoteplase in is...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-015-0307-2

    authors: Logallo N,Kvistad CE,Nacu A,Thomassen L

    更新日期:2016-02-01 00:00:00

  • Pharmacological management of neuropathic pain following spinal cord injury.

    abstract::Spinal cord injury (SCI) has a number of severe and disabling consequences, including chronic pain, and around 40% of patients develop persistent neuropathic pain. Pain following SCI has a detrimental impact on the patient's quality of life and is a major specific healthcare problem in its own right. Thus far, there i...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200822060-00002

    authors: Baastrup C,Finnerup NB

    更新日期:2008-01-01 00:00:00

  • Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update.

    abstract::Glutamatergic, noradrenergic, serotonergic, and cholinergic systems play a critical role in the basal ganglia circuitry. Targeting these non-dopaminergic receptors remains a focus of ongoing research to improve Parkinson's disease (PD) motor symptoms, without the potential side effects of dopamine replacement therapy....

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00754-0

    authors: Gonzalez-Latapi P,Bhowmick SS,Saranza G,Fox SH

    更新日期:2020-10-01 00:00:00

  • The new generation of GABA enhancers. Potential in the treatment of epilepsy.

    abstract::gamma-Aminobutyric acid (GABA) is considered to be the major inhibitory neurotransmitter in the brain and loss of GABA inhibition has been clearly implicated in epileptogenesis. GABA interacts with 3 types of receptor: GABAA, GABAB and GABAC. The GABAA receptor has provided an excellent target for the development of d...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115050-00001

    authors: Czuczwar SJ,Patsalos PN

    更新日期:2001-01-01 00:00:00

  • Aetiopathogenesis and pathophysiology of bulimia nervosa: biological bases and implications for treatment.

    abstract::Bulimia nervosa is an eating disorder characterised by recurrent episodes of binge eating and associated efforts to purge the ingested calories through self-induced vomiting, laxative or diuretic abuse, fasting or intensive exercise. The aetiopathogenesis and pathophysiology of the disorder are currently unclear. Biol...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115020-00004

    authors: Brambilla F

    更新日期:2001-01-01 00:00:00

  • Clinically important drug interactions with zopiclone, zolpidem and zaleplon.

    abstract::Insomnia, an inability to initiate or maintain sleep, affects approximately one-third of the American population. Conventional benzodiazepines, such as triazolam and midazolam, were the treatment of choice for short-term insomnia for many years but are associated with adverse effects such as rebound insomnia, withdraw...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317070-00004

    authors: Hesse LM,von Moltke LL,Greenblatt DJ

    更新日期:2003-01-01 00:00:00

  • Role of atypical antipsychotics in the treatment of generalized anxiety disorder.

    abstract::Evidence-based treatment approaches for generalized anxiety disorder (GAD) comprise psychotherapy, pharmacotherapy, or a combination of the two. First-line pharmacotherapy agents include selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, and, in certain European guidelines...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-014-0162-6

    authors: Hershenberg R,Gros DF,Brawman-Mintzer O

    更新日期:2014-06-01 00:00:00

  • Efficacy of olanzapine and ziprasidone for the treatment of schizophrenia: a systematic review.

    abstract::It is difficult to determine the relative efficacy of atypical antipsychotics for the treatment of schizophrenia, based on the available literature. The purpose of this article is to review and compare the efficacy of two atypical antipsychotics: olanzapine and ziprasidone.This review focused on randomised trials in w...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200519060-00003

    authors: Matza LS,Baker TM,Revicki DA

    更新日期:2005-01-01 00:00:00